Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marvel BiosciencesMBCOF 34 3-Year EBITDA Growth Rate is 19.30% as of Apr. 2026, which is 28% above its 10-year median of 15.10. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,137 Biotechnology companies, Marvel Biosciences ranks better than 55.41% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 0.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Marvel Biosciences was 19.30% per year. The lowest was -25.30% per year. And the median was 15.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Marvel Biosciences 3-Year EBITDA Growth Rate Related Terms
MBCOF vs VRTX, REGN, ALNY: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Marvel Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marvel Biosciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marvel Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Marvel Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.30% mean?
Marvel Biosciences (MBCOF) has a 3-Year EBITDA Growth Rate of 19.30% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Marvel Biosciences and its competitors. This is 28% above median its historical median of 15.10. According to the industry distribution chart, Marvel Biosciences ranks #507 out of 1137 companies in the Biotechnology industry, placing it in the top 44.6%.
Is Marvel Biosciences' 3-Year EBITDA Growth Rate too high?
Marvel Biosciences' current 3-Year EBITDA Growth Rate of 19.30% is 28% above median its 10-year median of 15.10. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Marvel Biosciences' value of 19.30% is 30.4% above this industry median. Based on the distribution chart, Marvel Biosciences ranks #507 out of 1137 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marvel Biosciences ranks #507 out of 1137 companies for 3-Year EBITDA Growth Rate. This puts Marvel Biosciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.80. Marvel Biosciences' value of 19.30% is 30.4% above this benchmark. While the company's 10-year median is 15.10 vs. the industry median of 14.80, Marvel Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,137 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marvel Biosciences's current 3-Year EBITDA Growth Rate of 19.30% is 30.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Marvel Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marvel Biosciences's current 3-Year EBITDA Growth Rate is 19.30%, which is 28% above median its own 10-year median of 15.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current 3-Year EBITDA Growth Rate of 19.30%. The current 3-Year EBITDA Growth Rate is 19.30%, which is 28% above median its 10-year median of 15.10 and 30.4% above the Biotechnology industry median of 14.80. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current 3-Year EBITDA Growth Rate is 19.30% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score
Get the complete analysis for MBCOF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBCOF has been successfully added to your 
